JeffreyRInfanteMD

Oncology • Nashville, TN

Hematologic Oncology

Director, Drug Development Program; Principal Investigator, Sarah Cannon Research Institute

Join to view full profile

Are you Dr. Infante?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 122 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
250 25th Ave N
Ste 100
Nashville, TN 37203
Phone+1 615-320-5090

Fax+1 615-320-1225
Is this information wrong?

Summary

Dr. Jeffrey Infante, MD is an oncologist in Nashville, Tennessee. He is currently licensed to practice medicine in Tennessee, Georgia, and Maryland. He is affiliated with TriStar Centennial Medical Center and Ascension Saint Thomas.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1999 - 2002
University of Florida College of MedicineClass of 1999

Certifications & Licensure

GA State Medical License 2021 - 2025
TN State Medical License 2006 - 2022
MD State Medical License 2004 - 2008
HI State Medical License 2002 - 2004
TX State Medical License 2002 - 2002

Awards, Honors, & Recognition

Board Certification, Medical Oncology ABIM

Clinical Trials

CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas Start of enrollment: 2007 Nov 01
Completed
Phase 1, Phase 2
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) Start of enrollment: 2007 Dec 14
Active, not recruiting
Phase 1
Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors Start of enrollment: 2008 Feb 01
Completed
Phase 1
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918 Start of enrollment: 2008 Aug 01
Terminated
Phase 1
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors Start of enrollment: 2008 Aug 01
Completed
Phase 1, Phase 2
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors Start of enrollment: 2010 Jul 01
Completed
Phase 1
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma Start of enrollment: 2010 Sep 28
Completed
Phase 1
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects Start of enrollment: 2011 Sep 01
Completed
Phase 1
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 1, Phase 2
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors Start of enrollment: 2012 Nov 27
Terminated
Phase 1, Phase 2
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor Start of enrollment: 2012 Dec 01
Completed
Phase 1
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Start of enrollment: 2013 Mar 01
Completed
Phase 1, Phase 2
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma Start of enrollment: 2013 Nov 01
Terminated
Phase 2
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies Start of enrollment: 2013 Jun 01
Terminated
Phase 1
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma Start of enrollment: 2013 Jul 01
Terminated
Phase 1
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Start of enrollment: 2013 Nov 15
Active, not recruiting
Phase 1
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies Start of enrollment: 2013 Dec 19
Completed
Phase 1
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Start of enrollment: 2014 Feb 01
Completed
Phase 1
A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001 Start of enrollment: 2014 Apr 01
Terminated
Phase 1
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma Start of enrollment: 2014 Jul 23
Completed
Phase 2
A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors Start of enrollment: 2013 Nov 01
Completed
Phase 1
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Start of enrollment: 2014 Oct 01
Completed
Phase 1, Phase 2
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies Start of enrollment: 2016 Jun 17
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

109 citations
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, s...
Saad Z. Usmani, Alfred L. Garfall, Niels W.C.J. van de Donk, Hareth Nahi, Jesús F. San-Miguel, Albert Oriol, Laura Rosiñol, Ajai Chari, Manisha Bhutani, Lionel Karlin,...> ;Lancet. 2021 Aug 21
45 citations
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type TP53.
Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald Steven Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme...> ;Clinical Cancer Research. 2021 Oct 1
19 citations
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors.
James J. Harding, Melinda L. Telli, Pamela N. Munster, Martin H. Voss, Jeffrey R. Infante, Angela DeMichele, Mark Dunphy, Mai H. Le, Christopher J. Molineaux, Keith W....> ;Clinical Cancer Research. 2021 Jul 20
12 citations
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant...
Charles G. Drake, Russell K. Pachynski, Sumit K. Subudhi, Douglas G. McNeel, Emmanuel S. Antonarakis, Todd M. Bauer, Peter Lauer, Dirk G. Brockstedt, Daniel Patricia, ...> ;Prostate Cancer and Prostatic Diseases. 2021 Jul 13
527 citations
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CART...
Jesus G. Berdeja, Deepu Madduri, Saad Z. Usmani, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, A. Keith Stewart, Parameswaran Hari, Myo Htut, Alexander M. Lesokhin,...> ;Lancet. 2021 Jul 24
91 citations
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced...
Gerald Steven Falchook, Jeffrey R. Infante, Hendrik-Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham P...> ;Eclinicalmedicine. 2021 Mar 30
11 citations
Pharmacokinetics and Safety of PTC596, a Novel Tubulin-Binding Agent, in Subjects With Advanced Solid Tumors
Geoffrey I. Shapiro, Edward O'Mara, Oscar L. Laskin, Lan Gao, John D. Baird, Robert J. Spiegel, Diksha Kaushik, Marla Weetall, Joseph M. Colacino, Kylie O'Keefe, Arthu...> ;Clinical Pharmacology in Drug Development. 2021 Jan 13
50 citations
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety ana...
Andrea B. Apolo, John Allan Ellerton, Jeffrey R. Infante, Manish Agrawal, Michael S. Gordon, Raid Aljumaily, Theodore Gourdin, Luc Dirix, Keun Wook Lee, Matthew H. Tay...> ;Journal for Immunotherapy of Cancer. 2020 Oct 1
8 citations
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
J. Randolph Hecht, Kyriakos P. Papadopoulos, Gerald Steven Falchook, Manish R. Patel, Jeffrey R. Infante, Raid Aljumaily, Deborah J. Wong, Karen A. Autio, Zev A. Wainb...> ;Investigational New Drugs. 2021 Feb 1
29 citations
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors.
Ani Sarkis Balmanoukian, Jeffrey R. Infante, Raid Aljumaily, Aung Naing, Ashish V. Chintakuntlawar, Naiyer A. Rizvi, Helen J. Ross, Michael S. Gordon, Philip Mallinder...> ;Clinical Cancer Research. 2020 Dec 1
89 citations
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Mark R. Middleton, Cheryl McAlpine, Victoria K Woodcock, Pippa Corrie, Jeffrey R. Infante, Neil Steven, Thomas R. Jeffry Evans, Alan Anthoney, Alexander N. Shoushtari,...> ;Clinical Cancer Research. 2020 Aug 18
15 citations
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.
Shahneen Sandhu, Catriona M. McNeil, Patricia LoRusso, Manish R. Patel, Omar Kabbarah, Chunze Li, Sandra Sanabria, W. Michael Flanagan, Ru-Fang Yeh, Flavia Brunstein, ...> ;Investigational New Drugs. 2020 Jun 1
23 citations
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
David E. Gerber, Jeffrey R. Infante, Michael S. Gordon, Sarah B. Goldberg, Miguel Martin, Enriqueta Felip, Maria Martinez Garcia, Joan H. Schiller, David R. Spigel, Ju...> ;Clinical Cancer Research. 2020 Jan 15
69 citations
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
Aung Naing, Deborah J. Wong, Jeffrey R. Infante, W. Michael Korn, Raid Aljumaily, Kyriakos P. Papadopoulos, Karen A. Autio, Shubham Pant, Todd M. Bauer, Alexandra Drak...> ;The Lancet. Oncology. 2019 Nov 1
15 citations
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
Aung Naing, Jeffrey R. Infante, Sanjay Goel, Howard A. Burris, Chelsea Black, Shannon Marshall, Ikbel Achour, Susannah Barbee, Rena May, Chris Morehouse, Kristen Polli...> ;Journal for Immunotherapy of Cancer. 2019 Aug 22
153 citations
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Rastilav Bahleda, Antoine Italiano, Cinta Hierro, Alain C. Mita, Andrés Cervantes, Nancy Chan, Mark M. Awad, Emiliano Calvo, Victor Moreno, Ramaswamy Govindan, Alexand...> ;Clinical Cancer Research. 2019 Aug 15
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
Huali Wu, Jeffrey R. Infante, Vicki L. Keedy, Suzanne F. Jones, Emily Chan, Johanna C. Bendell, Wooin Lee, Whitney P Kirschbrown, Beth A. Zamboni, Satoshi Ikeda, Hiros...> ;International Journal of Nanomedicine. 2019 Jul 24
159 citations
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Ryan J. Sullivan, Omid Hamid, Rene Gonzalez, Jeffrey R. Infante, Manish R. Patel, F. Stephen Hodi, Karl D. Lewis, Hussein Abdul-Hassan Tawbi, Genevive Hernandez, Matth...> ;Nature Medicine. 2019 Jun 1
39 citations
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Patrick A. Ott, Anna C. Pavlick, Douglas B. Johnson, Lowell L. Hart, Jeffrey R. Infante, Jason J. Luke, Jose Lutzky, Neal Evan Rothschild, Lynn E. Spitler, C. Lance Co...> ;Cancer. 2019 Apr 1
61 citations
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: Phase 1b results f...
Hyun Cheol Chung, Hendrik Tobias Arkenau, Jeeyun Lee, Sun Young Rha, Do Youn Oh, Lucjan Wyrwicz, Yoon-Koo Kang, Keun Wook Lee, Jeffrey R. Infante, Sung Sook Lee, M. Ma...> ;Journal for Immunotherapy of Cancer. 2019 Feb 4
144 citations
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8 + T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients.
Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Ivan H. Chan, Cong Shen, Navneet Ratti, Bianca Rojo, Karen A. Autio, Deborah J. Wong, Manish R. Patel, Patric...> ;Cancer Cell. 2018 Nov 12
51 citations
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
David S. Hong, Kathleen N. Moore, Manish R. Patel, Stefan C. Grant, Howard A. Burris, William N. William, Suzanne F. Jones, Funda Meric-Bernstam, Jeffrey R. Infante, L...> ;Clinical Cancer Research. 2018 Apr 11
117 citations
Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Leora Horn, Jeffrey R. Infante, Karen L. Reckamp, George R. Blumenschein, Ticiana A. Leal, Saiama N. Waqar, Barbara J. Gitlitz, Rachel E. Sanborn, Jennifer G. Whisenan...> ;Clinical Cancer Research. 2018 Jun 15
73 citations
Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinic...
Karen Kelly, Jeffrey R. Infante, Matthew H. Taylor, Manish R. Patel, Deborah J. Wong, Nicholas Iannotti, Janice M. Mehnert, Anja H. Loos, Helga Koch, Isabell Speit, Ja...> ;Cancer. 2018 May 1
31 citations
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients...
Carol Aghajanian, Katherine M. Bell-McGuinn, Howard A. Burris, Lillian L. Siu, Lee Ann Stayner, Jennifer J. Wheler, David S. Hong, Carla Kurkjian, Shubham Pant, Ademi ...> ;Investigational New Drugs. 2018 Apr 3
Join now to see all

Press Mentions

Stand up to Cancer Announces Four Teams Focused on Diversity in Early Phase Cancer Clinical TrialsFebruary 8th, 2023
Drug Developers Share Thoughts on the Oncology Pipeline and the Changes in Clinical TrialsMay 20th, 2022
Novel Interleukin-Based Immunotherapy Under Study in Pancreatic CancerDecember 29th, 2016
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Ascension Saint ThomasNashville, Tennessee
TriStar Centennial Medical CenterNashville, Tennessee